CTOs on the Move


 
ONE Bio Corp. is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.onehcorp.com
  • 19950 W Country Club Dr Ste 100
    Miami, FL USA 33180
  • Phone: 888.676.4445

Executives

Name Title Contact Details

Similar Companies

CerFlux

CerFlux Personalized Medicine aims to reduce the pain, reduce the discomfort, and reduce the cost of cancer treatment.

EGEN

EGEN is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quanterix

Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company`s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix` technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

Arvinas

Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.

Kurome Therapeutics

Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.